These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30223310)

  • 1. Type IV allergy to antimalarials can mimic cutaneous manifestations of lupus erythematosus.
    Borik L; Petzelbauer P; Quint T; Wöhrl S; Kinaciyan T; Heil PM
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):e94-e96. PubMed ID: 30223310
    [No Abstract]   [Full Text] [Related]  

  • 2. Early cutaneous eruptions after oral hydroxychloroquine in a lupus erythematosus patient: A case report and review of the published work.
    Matsuda T; Ly NTM; Kambe N; Nguyen CTH; Ueda-Hayakawa I; Son Y; Okamoto H
    J Dermatol; 2018 Mar; 45(3):344-348. PubMed ID: 29239026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxychloroquine-induced erythroderma.
    Pai SB; Sudershan B; Kuruvilla M; Kamath A; Suresh PK
    Indian J Pharmacol; 2017; 49(1):132-134. PubMed ID: 28458440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Eye toxicity of antimalarial agents].
    Graña Gil J; Cabana Vázquez M; Vázquez González A; Sánchez Meizoso MO
    An Med Interna; 2002 Apr; 19(4):189-91. PubMed ID: 12090061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye.
    Costedoat-Chalumeau N; Dunogué B; Leroux G; Morel N; Jallouli M; Le Guern V; Piette JC; Brézin AP; Melles RB; Marmor MF
    Clin Rev Allergy Immunol; 2015 Dec; 49(3):317-26. PubMed ID: 25672591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chloroquine, Hydroxychloroquine and Hearing Loss: A Study in Systemic Lupus Erythematosus Patients.
    Polanski JF; Tanaka EA; Barros H; Chuchene AG; Miguel PTG; Skare TL
    Laryngoscope; 2021 Mar; 131(3):E957-E960. PubMed ID: 32603516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimalarial drug-induced aquagenic-type pruritus in patients with lupus.
    Jiménez-Alonso J; Tercedor J; Jáimez L; García-Lora E
    Arthritis Rheum; 1998 Apr; 41(4):744-5. PubMed ID: 9550488
    [No Abstract]   [Full Text] [Related]  

  • 8. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.
    Mittal L; Zhang L; Feng R; Werth VP
    J Am Acad Dermatol; 2018 Jan; 78(1):100-106.e1. PubMed ID: 28989103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects.
    Tang C; Godfrey T; Stawell R; Nikpour M
    Intern Med J; 2012 Sep; 42(9):968-78. PubMed ID: 22827853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generalized skin hyperpigmentation and longitudinal melanonychia secondary to treatment with hydroxychloroquine in systemic lupus erythematosus.
    Sifuentes Giraldo WA; Grandal Platero M; de la Puente Bujidos C; Gámir Gámir ML
    Reumatol Clin; 2013; 9(6):381-2. PubMed ID: 23481508
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic efficacy and adverse events of hydroxychloroquine administration in Japanese systemic/cutaneous lupus erythematosus patients.
    Kishi C; Motegi SI; Yasuda M; Ishikawa O
    J Dermatol; 2018 Aug; 45(8):1020-1022. PubMed ID: 30133802
    [No Abstract]   [Full Text] [Related]  

  • 12. [Acute generalized exanthematous pustulosis included by hydroxychloroquine during lupus].
    Fain O; Stirnemann J; Kettaneh A
    Rev Prat; 2010 Jan; 60(1):20. PubMed ID: 20222305
    [No Abstract]   [Full Text] [Related]  

  • 13. A 6-step rapid desensitization protocol to hydroxychloroquine.
    Sutton KM; Fernando SL
    Ann Allergy Asthma Immunol; 2021 Mar; 126(3):292-293. PubMed ID: 33276119
    [No Abstract]   [Full Text] [Related]  

  • 14. Hydroxychloroquine and chloroquine: assessing the risk of retinal toxicity.
    Aylward JM
    J Am Optom Assoc; 1993 Nov; 64(11):787-97. PubMed ID: 8120333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral manifestations associated with antimalarial therapy in patients with systemic lupus erythematosus.
    Chacón-Dulcey V; López-Labady J; Villarroel-Dorrego M; Frías J; Tirado W; González N; Pérez Alfonzo R
    Lupus; 2020 Jun; 29(7):761-766. PubMed ID: 32362181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimalarial therapy in SLE.
    Lanham JG; Hughes GR
    Clin Rheum Dis; 1982 Apr; 8(1):279-98. PubMed ID: 6749400
    [No Abstract]   [Full Text] [Related]  

  • 17. Adverse cutaneous drug reactions with antimalarials in cutaneous lupus and dermatomyositis: A retrospective cohort study.
    Gonzalez CD; Hansen C; Clarke JT
    J Am Acad Dermatol; 2019 Sep; 81(3):859-860. PubMed ID: 31085265
    [No Abstract]   [Full Text] [Related]  

  • 18. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
    Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
    Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Antimalarial Therapy in Patients Who Are Hypersensitive to Hydroxychloroquine.
    Riley K; Schwager Z; Stern M; Vleugels RA; Femia A
    JAMA Dermatol; 2019 Apr; 155(4):491-493. PubMed ID: 30758479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exacerbations of bipolar disorder triggered by chloroquine in systemic lupus erythematosus--a case report.
    Bogaczewicz J; Sobów T; Bogaczewicz A; Robak E; Bienkowski P; Sysa-Jedrzejowska A; Wozniacka A
    Lupus; 2014 Feb; 23(2):188-93. PubMed ID: 24297641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.